Stanford prof. turns terminal cancer diagnosis into life-changing lesson for students, world
The 10-week course at Stanford last fall was fully enrolled and packed with students eager to learn from Dr. Lin's unique ...
MyStateline.com on MSN3h
Rockford doctor works with her students to find quicker ways to detect lung cancer
Dr. Neelu Puri is leading lung cancer research at the University of Illinois College of Medicine Rockford, promoting early ...
Increased use of chest X-rays linked to earlier lung cancer diagnosis and improved survival
A groundbreaking study has revealed a significant link between the frequency of chest X-ray referrals from GPs and earlier ...
CURE11h
First Patient Dosed with Efti in Phase 3 Trial for Non-Small Cell Lung Cancer
The first patient has been dosed in the phase 3 TACTI-004 trial evaluating efti with Keytruda and chemotherapy for advanced ...
'Healthy' man, 36, told he'll die from cancer after terrifying warning sign at 3am
George Dudnik, 36, was told he was far too young and fit to be diagnosed with cancer – but after a series of terrifying ...
Medscape8d
Does Invasive Staging Improve NSCLC Survival Outcomes?
A recent analysis shows that additional invasive staging modalities lead to relevant changes in target volume in some patients with NSCLC but do not impact survival.
Healio1d
‘It can save their lives’: Annual lung cancer screening improves cancer detection rate
Annual lung cancer screening, or LCS, detects cancer at a higher rate and at earlier stages, findings suggest.According to Roger Y. Kim, MD, MSCE, DAABIP, ATSF, an assistant professor of medicine at ...
CURE10h
Olvi-Vec Shows Responses and Tolerable Safety in Small Cell Lung Cancer
Positive preliminary data from the phase 1b/2 trial evaluating Olvi-Vec in small cell lung cancer have been announced.
New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings
New study results presented at the European Lung Cancer Congress (ELCC) 2025, March 26 to 29, demonstrate the role of AstraZeneca’s TAGRISSO® (osimertinib), as monotherapy and as the backbone for ...